Revolutionary blood test monitors gene expression dynamics in the brain

The results from a global Phase III trial funded by Novo Nordisk found significant symptom improvement in patients with preserved ejection fraction (HFpEF). Image credit:

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) Cus­tomers of Sesame … Sign up to

The FDA approved injectable Jubbonti and Wyost as the first interchangeable biosimilars to denosumab (Prolia, Xgeva), and for all the same indications, including the prevention